Amyotrophic Lateral Sclerosis (ALS)

Neurology·MeSH: Amyotrophic Lateral Sclerosis

Prevalence

5.0 / 100K

Incidence

2.0 / 100K/yr

20 drugs in development·13 companies·6 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
Emylif® (licensed product, formerly Exservan® in U.S.)	Aquestive Therapeutics, Inc. (AQST)

Phase 2(8)

Drug	Company
Autologous Treg cell therapy	Coya Therapeutics, Inc. (COYA)
COYA 301	Coya Therapeutics, Inc. (COYA)
COYA 302	Coya Therapeutics, Inc. (COYA)
COYA 303	Coya Therapeutics, Inc. (COYA)
tegoprubart	Eledon Pharmaceuticals, Inc. (ELDN)
Utreloxastat	PTC THERAPEUTICS, INC. (PTCT)
vhb937	Novartis AG (NVS)
vhb937	Novartis AG (NVS)

Phase 1(2)

Drug	Company
pas-003	Pasithea Therapeutics Corp. (KTTA)
rinvatercept	Keros Therapeutics, Inc. (KROS)

Preclinical(8)

Drug	Company
aav-upf1	MeiraGTx Holdings plc (MGTX)
ALPHA-0602	Alpha Cognition Inc. (ACOG)
ALPHA-0702	Alpha Cognition Inc. (ACOG)
ALPHA-0802	Alpha Cognition Inc. (ACOG)
als program	Korro Bio, Inc. (KRRO)
rpi-78m	NUTRA PHARMA CORP (NPHC)
sod1 silencing gene therapy	Voyager Therapeutics, Inc. (VYGR)
undisclosed als program	Korro Bio, Inc. (KRRO)

Phase 2/Phase 3(1)

Drug	Company
ath-1105	LeonaBio, Inc. (LONA)

BioSniper tracks 20 drugs in development for Amyotrophic Lateral Sclerosis (ALS) across 13 companies.

There are 6 clinical trials targeting Amyotrophic Lateral Sclerosis (ALS) tracked by BioSniper.

The estimated prevalence of Amyotrophic Lateral Sclerosis (ALS) is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.